Alliancebernstein L.P. Has $311.70 Million Stock Holdings in Genmab A/S (NASDAQ:GMAB)

Alliancebernstein L.P. trimmed its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 1.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,935,224 shares of the company's stock after selling 200,928 shares during the period. Alliancebernstein L.P. owned 2.26% of Genmab A/S worth $311,698,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brandywine Global Investment Management LLC acquired a new position in Genmab A/S during the 4th quarter valued at about $33,804,000. Two Sigma Advisers LP increased its stake in shares of Genmab A/S by 84.1% during the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock valued at $14,996,000 after acquiring an additional 280,900 shares during the period. JPMorgan Chase & Co. raised its holdings in Genmab A/S by 3,049.3% during the fourth quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company's stock worth $8,507,000 after purchasing an additional 394,670 shares in the last quarter. FMR LLC raised its holdings in Genmab A/S by 13.5% during the third quarter. FMR LLC now owns 278,194 shares of the company's stock worth $6,782,000 after purchasing an additional 33,076 shares in the last quarter. Finally, LPL Financial LLC lifted its position in Genmab A/S by 3.3% in the fourth quarter. LPL Financial LLC now owns 195,436 shares of the company's stock worth $4,079,000 after purchasing an additional 6,288 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Price Performance

NASDAQ GMAB traded up $0.42 on Thursday, hitting $19.24. 1,715,372 shares of the stock were exchanged, compared to its average volume of 973,396. The company's 50-day moving average price is $20.76 and its two-hundred day moving average price is $21.71. The company has a market capitalization of $12.73 billion, a price-to-earnings ratio of 11.06, a P/E/G ratio of 2.65 and a beta of 0.98. Genmab A/S has a 52-week low of $18.48 and a 52-week high of $30.50.

Remove Ads

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Equities analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on GMAB shares. Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective on the stock in a research note on Thursday, February 13th. Truist Financial cut their price target on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Finally, BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $41.33.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.